The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis
Cancer · 2026
DOI: 10.1002/cncr.70268 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer, 2026. Verfasst von Yiwen Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Breast Neoplasms, Brain Neoplasms, Trastuzumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Liaoning Provincial Key R&D Projects, Shenyang Public Health R&D Special Project, Shenyang Breast Cancer Clinical Medical Research Center.
Abstract (Originalsprache)
Background
Although trastuzumab deruxtecan (T‐DXd) demonstrated unprecedented intracranial efficacy in HER2‐positive breast cancer brain metastases (BCBM), its association with interstitial lung disease (ILD)/pneumonitis posed a critical safety concern in this high‐risk population. Previous safety assessments lacked BCBM‐specific analysis of ILD.
Methods
This systematic review and meta‐analysis (PROSPERO identifier CRD420251130832) followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. The authors searched the PubMed, Embase, Web of Science, and Cochrane databases and major oncology conferences through July 2025 for studies that reported T‐DXd‐related, treatment‐emergent adverse events (TEAEs) in patients with HER2‐positive BCBM, focusing on ILD/pneumonitis incidence and severity. Pooled rates were calculated using random effects models.
Results
In total, nine studies involving 684 patients with BCBM were included. The pooled incidence rates for all‐grade and grade ≥3 ILD/pneumonitis were 10% (95% confidence interval [CI], 5%–16%) and 2% (95% CI, 1%–4%), respectively. ILD/pneumonitis led to discontinuation in 11% (95% CI, 0%–24%) of patients with BCBM. No fatal ILD events were reported. Overall, any‐grade TEAEs occurred in 97% of patients, with grade ≥3 TEAEs occurring in 48%. Fatigue and nausea were the most prevalent all‐grade TEAEs, with incidences of 67% and 60%, respectively.
Conclusions
In patients with BCBM, T‐DXd–associated ILD/pneumonitis occurred in 10% of patient and frequently necessitated treatment modification. Although no fatal ILD was observed, the high discontinuation rate underscored the imperative for vigilant monitoring and protocol‐guided management to mitigate pulmonary toxicity while preserving intracranial efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Förderung
- Liaoning Provincial Key R&D Projects
- Shenyang Public Health R&D Special Project
- Shenyang Breast Cancer Clinical Medical Research Center
- Liaoning Province Joint Fund Project
- Liaoning Cancer Hospital "Oncology+" Project
Zitieren
APA
Ma, Y., Li, X., Jiang, Y., Xiao, L., & Sun, T. (2026). The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis. Cancer. https://doi.org/10.1002/cncr.70268
Vancouver
Ma Y, Li X, Jiang Y, Xiao L, Sun T. The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis. Cancer. 2026. doi:10.1002/cncr.70268
BibTeX
@article{Ma2026,
author = {Ma, Yiwen and Li, Xiaorui and Jiang, Yujun and Xiao, Liping and Sun, Tao},
title = {The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70268}
}
EUVIMED